NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer No drug interventions Not Available Not Available available NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies No drug interventions treatment 1 completed NCT01500733
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 active_not_recruiting NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL treatment 1 / 2 completed NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL treatment 2 terminated NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL No drug interventions treatment 1 withdrawn NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT04704323
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia No drug interventions treatment 1 recruiting NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) No drug interventions treatment 3 recruiting NCT02046928
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL No drug interventions treatment 1 / 2 terminated NCT04694560
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma No drug interventions Not Available Not Available withdrawn NCT02863692
Registry of the German CLL Study Group No drug interventions Not Available Not Available recruiting NCT00980395
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma No drug interventions treatment 2 completed NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT03588598
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies No drug interventions treatment 1 unknown_status NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 recruiting NCT03406156
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy treatment 3 completed NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) treatment 2 withdrawn NCT04419519
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax treatment 2 recruiting NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL treatment 2 terminated NCT03788291
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT00694590
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 completed NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 2 active_not_recruiting NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05168930
Zanubrutinib and Venetoclax in CLL (ZANU-VEN) No drug interventions treatment 2 recruiting NCT05708326
A Case Crossover Study of Intermittent Fasting in CLL/SLL No drug interventions prevention Not Available completed NCT03702231
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) No drug interventions basic_science 2 completed NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 1 terminated NCT01181271
Tandem Auto-Allo Transplant for Lymphoma treatment 2 completed NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) treatment 2 terminated NCT00143065
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT00083473
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia treatment 2 terminated NCT00060684
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 1 / 2 recruiting NCT00081809
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma No drug interventions treatment 2 completed NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL No drug interventions Not Available Not Available terminated NCT02292225
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) No drug interventions treatment 1 terminated NCT02677948
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 / 2 withdrawn NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas No drug interventions treatment 2 completed NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers No drug interventions treatment 3 unknown_status NCT04626843
Intermittent Fasting and CLL/SLL No drug interventions treatment 1 completed NCT03420183
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies treatment 1 / 2 recruiting NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study No drug interventions treatment 3 recruiting NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 3 active_not_recruiting NCT01306643
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma No drug interventions treatment 1 / 2 completed NCT01722487
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL treatment 3 completed NCT02135133
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL treatment 2 active_not_recruiting NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL treatment 3 active_not_recruiting NCT06364033
Biological and Clinical Efficacy of Shingrix in Patients With CLL No drug interventions basic_science Not Available not_yet_recruiting NCT04624633
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL treatment 2 active_not_recruiting NCT01000753
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT01105247
Safety of PCI-32765 in Chronic Lymphocytic Leukemia treatment 1 / 2 completed NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT06520098
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) treatment 2 not_yet_recruiting NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies No drug interventions treatment 1 completed NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma treatment 2 / 3 terminated NCT02514083
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL treatment 2 active_not_recruiting NCT00100711
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 terminated NCT01161511
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia treatment 1 completed NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) treatment 3 recruiting NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT01578707
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia treatment 3 completed NCT00923507
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) No drug interventions Not Available Not Available recruiting NCT04771507
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 recruiting NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 treatment 2 terminated NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL treatment 1 completed NCT02049515
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 treatment 3 completed NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) treatment 2 withdrawn NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT04867915
Study on the Diagnosis and Management of CLL in Italy by GIMEMA No drug interventions Not Available Not Available recruiting NCT01113632
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 completed NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma treatment 2 terminated NCT01239875
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma treatment 0 completed NCT05388006
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 recruiting NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT05317936
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax treatment 2 recruiting NCT04176913
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 terminated NCT02048813
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 3 active_not_recruiting NCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 completed NCT02296918
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL treatment 1 active_not_recruiting NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT05677919
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia treatment 2 recruiting NCT04623541
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome treatment 1 / 2 recruiting NCT03516617
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 recruiting NCT02784834
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL treatment 1 terminated NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT01682616
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 completed NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia treatment 3 completed NCT01497496
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) treatment 2 completed NCT01351896
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT01292135
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) treatment 1 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) treatment 3 enrolling_by_invitation NCT04852822
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions Not Available Not Available terminated NCT04560322
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL treatment 2 recruiting NCT01832922
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction treatment 1 completed NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia prevention 2 recruiting NCT06367374
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL treatment 2 not_yet_recruiting NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas treatment 1 active_not_recruiting NCT00201682
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma treatment 1 / 2 completed NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT00439231
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 completed NCT01496976
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL treatment 2 active_not_recruiting NCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . No drug interventions treatment 1 / 2 recruiting NCT01419691
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT02086591
A Phase II Study of Doxycycline in Relapsed NHL treatment 2 terminated NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) treatment 3 active_not_recruiting NCT02337829
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL treatment 2 active_not_recruiting NCT03892044
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma No drug interventions treatment 1 completed NCT04155840
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies No drug interventions treatment 1 / 2 withdrawn NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT04722172
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL No drug interventions treatment 2 active_not_recruiting NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT05718869
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study No drug interventions treatment 2 recruiting NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 3 completed NCT03737981
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 3 active_not_recruiting NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL No drug interventions treatment 1 / 2 completed NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas No drug interventions treatment 2 completed NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome No drug interventions treatment 2 recruiting NCT04504708
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies No drug interventions treatment 1 / 2 terminated NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia No drug interventions treatment 2 recruiting NCT04666038
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 3 active_not_recruiting NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia No drug interventions treatment 1 / 2 active_not_recruiting NCT00759603
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL No drug interventions treatment 1 / 2 recruiting NCT01611090
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 3 completed NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation No drug interventions treatment 2 active_not_recruiting NCT05287984
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL No drug interventions treatment 2 not_yet_recruiting NCT01173679
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL No drug interventions treatment 2 terminated NCT01973387
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma No drug interventions treatment 3 completed NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor No drug interventions treatment 1 withdrawn NCT00974233
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL No drug interventions treatment 2 completed NCT05183854
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial No drug interventions treatment 2 recruiting NCT04505254
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT04094051
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice No drug interventions Not Available Not Available unknown_status NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 completed NCT01862445
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients No drug interventions Not Available Not Available unknown_status NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT02756897
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT02910583
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 2 completed NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT03422393
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib No drug interventions treatment 1 active_not_recruiting NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 terminated NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 / 2 active_not_recruiting NCT05521178
Cardiotoxicities in Patients Receiving BTKi No drug interventions Not Available Not Available withdrawn NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL No drug interventions treatment 1 terminated NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency No drug interventions treatment Not Available recruiting NCT02629809
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT01145209
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL No drug interventions treatment 2 completed NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies No drug interventions treatment 1 terminated NCT03370185
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No drug interventions treatment 2 withdrawn NCT06544785
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) No drug interventions prevention 2 completed NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies No drug interventions treatment 1 completed NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) No drug interventions treatment 3 recruiting NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) No drug interventions treatment 3 withdrawn NCT01117142
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers No drug interventions Not Available Not Available completed NCT01217749
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL No drug interventions treatment 1 / 2 completed NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT02825836
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects No drug interventions treatment 1 / 2 active_not_recruiting NCT02529813
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 completed NCT05272813
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL No drug interventions treatment 1 / 2 terminated NCT04578613
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL No drug interventions treatment 3 recruiting NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 2 completed NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT00849524
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 2 terminated NCT01241786
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL No drug interventions treatment 2 terminated NCT02004522
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) No drug interventions treatment 3 completed NCT06466122
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi No drug interventions treatment 2 recruiting NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553 No drug interventions treatment 1 / 2 terminated NCT03801525
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) No drug interventions treatment 2 / 3 terminated NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 terminated NCT03828448
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma No drug interventions treatment 2 terminated NCT00873457
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT00850057
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 completed NCT01754857
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL No drug interventions treatment 2 completed NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 withdrawn NCT06291220
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) No drug interventions treatment 1 recruiting NCT03701282
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia No drug interventions treatment 3 active_not_recruiting NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma No drug interventions treatment 2 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients No drug interventions prevention 2 terminated NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies No drug interventions treatment 2 completed NCT03035331
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT00535873
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older No drug interventions treatment 2 completed NCT01650727
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) No drug interventions treatment 1 completed NCT01239394
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma No drug interventions treatment 2 completed NCT05479994
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 recruiting NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma No drug interventions treatment 2 terminated NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers No drug interventions treatment 1 active_not_recruiting NCT06547944
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) No drug interventions treatment 1 active_not_recruiting NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL No drug interventions treatment 1 / 2 recruiting NCT05147467
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL No drug interventions treatment 2 recruiting NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 active_not_recruiting NCT04843904
Safe Accelerated Venetoclax Escalation in CLL No drug interventions treatment 1 recruiting NCT00290004
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 1 / 2 completed NCT01010568
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT01724346
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 3 completed NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 terminated NCT05336812
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia No drug interventions treatment 2 recruiting NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL No drug interventions treatment 2 recruiting NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL No drug interventions treatment 1 / 2 active_not_recruiting NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi No drug interventions treatment 2 completed NCT00234481
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia No drug interventions treatment 1 terminated NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. No drug interventions treatment 3 completed NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma No drug interventions treatment 1 terminated NCT02518555
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma No drug interventions supportive_care 3 completed NCT03019055
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell No drug interventions treatment 1 completed NCT01002755
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No drug interventions treatment 2 completed NCT04682808
A Study of FCN-338 in Patients With Chronic CLL/SLL No drug interventions treatment 1 active_not_recruiting NCT05371808
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: No drug interventions Not Available Not Available recruiting NCT04994587
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 recruiting